Mamacrowd and CrowdFundMe Launch First Campaigns with New European Regulation

The week after obtaining Consob’s authorization to operate under the new European crowdfunding regulation, the Mamacrowd and CrowdFundMe platforms launched the first equity crowdfunding campaigns on their portal.

Read more about the first campaigns launched on Mamacrowd and CrowdFundMe after the platforms were authorized to function under the new European regulation, and read the most important business news of the day with the Born2Invest mobile app.

Mamacrowd first campaign

A campaign has started on Mamacrowd for Opificio Fred, a Friuli-based company specializing in the production of artisanal distilled spirits and liqueurs made in Italy founded by Federico Cremasco, an expert herbalist with consolidated experience in the spirits & mixology sector.

The minimum raising target for the campaign launched on Mamacrowd is €100,000 and the maximum is €500,000, against a pre-money valuation of €1.75 million.

On the strength of steady growth, Opificio Fred’s story has developed from the beginning on the international axis and especially on the Italian-American axis.

Two main distributors have espoused its philosophy and distinctive elements: Spirits & Colori for Italy, and Oliver McCrum Wine & Spirits for the United States. This is joined by new countries and importers, such as Japan, Canada, Belgium, Slovenia, Austria, and Mexico.

The company, which expects to close in 2023 with a turnover of more than €400,000, has grown in terms of revenues, by more than 45 percent in two years, compared to 2021, the year of the previous crowdfunding capital increase.

CrowdFundMe

Euronext’s Growth-listed platform CrowdFundMe has launched campaigns for two innovative startups, Euleria Health and Myra Nutricosmetics.

Euleria Health, a benefit company, is dedicated to the research and development of devices to innovate the world of rehabilitation.

The company has a minimum raising target of €100,000 and a maximum of €2.5 million, against a pre-money valuation of €6.8 million.

The company’s proprietary technologies are designed to assist both professionals and patients at every stage of the recovery journey, improving clinical outcomes and enabling optimal supervision even remotely, in the clinical setting, and at home.

The company is producing tangible results in terms of revenues: it has revenues of € 910,000 in 2022 (up 60 percent from 2021) and has a portfolio of more than 300 clients, including rehabilitation centers and clinics, as well as more than 30,000 patients, from Europe to China.

Myra Nutricosmetics is an innovative startup focused on the development, promotion, and distribution of nutricosmetics belonging to the proprietary brand ABSOLOGY.

The startup has a minimum raising target of €50,000 and a maximum of €200,000, with a pre-money valuation of €650,000.

Absology offers 8 lines of hair, skin, and wellness beauty products and upholds the principles of Clean Beauty: all treatments are natural and planet- and skin-friendly, while the packaging is FSC (Forest Stewardship Council) certified and recyclable.

Myra Nutricosmetics thus offers “premium” items, already purchased in France and Italy, and collaborates with pharmaceutical development and manufacturing entities such as Catalent Italy, Strapharm France, and Novapharm France.

Although it has only been operational since March 2023, the company has already achieved a turnover of €127,000 with more than 2,000 orders and has closed important distribution agreements with major players in the industry.

__

(Featured image by 12019 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us